Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Debt / NOTE 3.250% 7/0
-
Number of holders
-
24
-
Total 13F principal, excl. options
-
82.8M
-
Principal change
-
-332K
-
Total reported value, excl. options
-
$79.2M
-
Value change
-
-$6.47K
-
Number of buys
-
7
-
Number of sells
-
-9
-
Price
-
$0.95
Significant Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q4 2021
28 filings reported holding 45845PAA6 - INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q4 2021.
INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 has 24 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $82.8M of principal
.
Largest 10 bondholders include DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) ($57.8M of principal), OAKTREE CAPITAL MANAGEMENT LP ($6.49M of principal), MORGAN STANLEY ($3.86M of principal), Kohlberg Kravis Roberts & Co. L.P. ($3.32M of principal), BlackRock Inc. ($3.05M of principal), Saltoro Capital, LP ($1.8M of principal), STATE STREET CORP ($1.52M of principal), Russell Investments Group, Ltd. ($1.51M of principal), Parallax Volatility Advisers, L.P. ($1M of principal), and L & S Advisors Inc ($895K of principal).
This table shows the top 24 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.